- HYDROXY-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS
-
The present invention is directed to hydroxy compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric dis
- -
-
-
- TROPANE COMPOUNDS
-
A compound according to Formula I or II: (I) or (II) wherein R1, R1b, R2, L1, and L2 and L2b are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.
- -
-
Page/Page column 392
(2009/05/30)
-
- Ultra-Sensitive Chemiluminescent Substrates for Enzymes and Their Conjugates
-
New chemiluminescent compounds, stable in aqueous buffers, for use in biological assaying include acridanebased compounds and (1,2)-dioxetanes. Among the new acridanebased compounds are water-soluble acridanes, enhancer coupled acridanes, bis and trisacri
- -
-
Page/Page column 29
(2010/11/28)
-
- CARBAMOYL-TYPE BENZOFURAN DERIVATIVES
-
The present invention provides a carbamoyl-type benzofuran derivative of the formula [1]: wherein Ring Z is a group of the formula: etc.; A is a single bond, and the like; Y is a cycloalkanediyl group, etc.; R4 and R5 are the same or different and each is an optionally substituted lower alkyl group, etc.; R1 is a halogen atom, etc.; Ring B of the formula: is an optionally substituted benzene ring; and R3 is a hydrogen atom, etc., or a pharmaceutically acceptable salt thereof, which is useful as an FXa inhibitor.
- -
-
Page/Page column 90
(2008/06/13)
-
- Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: Combining X-ray crystallography, 3D-QSAR, and tailored scoring functions
-
The design, synthesis, and structure-activity relationship of 3-oxybenzamides as potent inhibitors of the coagulation protease factor Xa are described on the basis of X-ray structures, privileged structure motifs, and SAR information. A total of six X-ray structures of fXa/inhibitor complexes led us to identify the major protein-ligand interactions. The binding mode is characterized by a lipophilic dichlorophenyl substituent interacting with Tyr228 in the protease S1 pocket, while polar parts are accommodated in S4. This alignment in combination with docking allowed derivation of 3D-QSAR models and tailored scoring functions to rationalize biological affinity and provide guidelines for optimization. The resulting models showed good correlation coefficients and predictions of external test sets. Furthermore, they correspond to binding site topologies in terms of steric, electrostatic, and hydrophobic complementarity. Two approaches to derive tailored scoring functions combining binding site and ligand information led to predictive models with acceptable predictions of the external set. Good correlations to experimental affinities were obtained for both AFMoC (adaptation of fields for molecular comparison) and the novel TScore function. The SAR information from 3D-QSAR and tailored scoring functions agrees with all experimental data and provides guidelines and reasonable activity estimations for novel fXa inhibitors.
- Matter, Hans,Will, David W.,Nazaré, Marc,Schreuder, Herman,Laux, Volker,Wehner, Volkmar
-
p. 3290 - 3312
(2007/10/03)
-
- BENZOFURAN DERIVATIVE
-
The present invention provides a benzofuran derivative of the formula [1]: wherein x is a group of the formula: -N="or" -CH=; Y is an optionally substituted amino group, an optionally substituted cycloalkyl group or an optionally substituted saturated heterocyclic group; A is a single bond, a carbon chain optionally having a double bond within or at the end(s) of the chain, or an oxygen atom; R1 is a hydrogen atom or a halogen atom; Ring B is an optionally substituted benzene ring; and R3 is a hydrogen atom, or a pharmaceutically acceptable salt thereof, which is useful as a medicament, especially as an activated blood coagulation factor X inhibitor.
- -
-
Page 195-196
(2008/06/13)
-
- Prenyl transferase inhibitors
-
A family of imidazole compounds useful for inhibiting the activity of prenyl transferases. The compounds are covered by the following formula: wherein X is (CHR11)n3(CH2)n4Z(CH2)n5 where Z is O, N(R12), S, or a bond; Y is CO, CH2, CS, or a bond; R1 is or N(R24R23); and the remaining substituents are as defined in the disclosure.
- -
-
-
- Method of treating cancer
-
The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase. The invention also relates to methods of preparing such compositions.
- -
-
-
- INHIBITORS OF PRENYL-PROTEIN TRANSFERASE
-
The present invention is directed to compounds which inhibit prenyl-protein transferases, farnesyl-protein transferase and geranylgeranyl-protein transferase type I, and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and geranylgeranyl-protein transferase type I and the prenylation of the oncogene protein RAS.
- -
-
-
- Inhibitors of prenyl-protein transferase
-
The present invention is directed to compounds which inhibit a prenyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting a prenyl-protein transferase and the prenylation of the oncogene protein Ras.
- -
-
-
- Diaryl ether inhibitors of farnesyl-protein transferase
-
Imidazolemethyl diaryl ethers are potent inhibitors of farnesyl-protein transferase. The SNAr displacement reaction used to prepare these diaryl ethers was amenable to rapid parallel synthesis of FPTase inhibitors. The use of a broad range of c
- MacTough, Suzanne C.,Desolms, S. Jane,Shaw, Anthony W.,Abrams, Marc T.,Ciccarone, Terrence M.,Davide, Joseph P.,Hamilton, Kelly A.,Hutchinson, John H.,Koblan, Kenneth S.,Kohl, Nancy E.,Lobell, Robert B.,Robinson, Ronald G.,Graham, Samuel L.
-
p. 1257 - 1260
(2007/10/03)
-
- INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE
-
The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
- -
-
-
- Isolation of bright blue fluorescent substances from sonochemical hydroxylation of methyl p-cyanobenzoate
-
Sonochemical hydroxylation of methyl p-cyanobenzoate (1a) in water gave a bright blue fluorescence, which are mainly ascribed to three new fluorescent compounds, 3-hydroxy, 2,3- and 2,5-dihydroxy derivatives of 1a. Other benzenes substituted with electron-withdrawing groups also gave similar fluorescence from their hydroxylated derivatives. Among the fluorescence substances, methyl 2,5-dihydroxybenzoate was supposed to be applicable for a fluorescent chemosensor.
- Yamada, Sachiko,Hokari, Hajime,Akasaka, Shinji,Iwamura, Michiko
-
p. 197 - 198
(2007/10/03)
-